As Britain’s departure date from the European Union approaches, drugmakers are preparing for potential changes to regulatory procedures and border controls.

If the UK leaves the EU in March without a deal, transport of insulin and other essential drugs could be delayed.

The plan would also allow non-EU countries to pay to participate in EU research programs, albeit without wielding “decisional power.”

The budget is smaller than what some researchers hoped for, and too high for at least one EU member state.

Alzheimer’s researcher John Hardy calls the departure “an unmitigated disaster” for science and healthcare in Britain.

Gender discrimination, Brexit, and climate change are among the issues that have received considerable attention from the scientific community this year.

A coin toss decides the agency’s post-Brexit home once it departs from London.

The $88 million agreement is part of efforts by the UK government to increase transatlantic collaboration as the country prepares to leave the European Union.

Some researchers have already been negatively affected by the U.K.’s decision to leave the European Union, though opinions on the eventual outcome remain mixed.